Document is current
Any future updates will be listed below
-
Authors
Argenziano, Michael G.
Neelakantan, Taruna V.
Sperring, Colin
Adeuyan, Oluwaseyi
Higgins, Dominique M. O.
Bruce, Jeffrey N. https://orcid.org/0000-0002-6844-0286
Kim, Betty Y. S. https://orcid.org/0000-0001-6890-8355
Dovas, Athanassios
Canoll, Peter
Lim, Michael https://orcid.org/0000-0003-0523-3076
Stockwell, Brent R. https://orcid.org/0000-0002-3532-3868
Banu, Matei A. https://orcid.org/0000-0003-2330-1810
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (K12/NRCDP)
- License Information
-
More Information
Article History
Received: 18 November 2024
Accepted: 29 April 2026
First Online: 1 June 2026
Competing interests
: B.R.S. is an inventor on patents and patent applications involving ferroptosis, has co-founded and serves as consultant to ProJenX, Inc. and Exarta Therapeutics, holds equity in Sonata Therapeutics, and serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer & Feld LLP. J.N.B. and P.C. are the founders of Convecta Therapeutics, a company developing convection enhanced delivery drug formulations. J.N.B. is also a consultant for Theracle, Inc., which designs catheters for drug delivery to the brain. M.L. has obtained funding from Arbor Pharmaceuticals, Accuray, BMS and Novartis, and serves as consultant for BMS, Merck, SQZ Biotechnologies, Tocagen and VBI. M.L. is a shareholder in Egret Therapeutics. The remaining authors declare no competing interests.
